Myriad Genetics (MYGN) Common Equity (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Common Equity data on file, last reported at $337.4 million in Q1 2026.

• Common Equity for Q1 2026 came in at $337.4 million, down 52.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $337.4 million (down 52.14% YoY), and the FY2025 annual result was $368.0 million, down 47.51% from the prior year.
• Common Equity eased to $337.4 million in Q1 2026 per MYGN's latest filing, from $368.0 million in the prior quarter.
• Over five years, Common Equity peaked at $950.1 million in Q1 2022 and troughed at $337.4 million in Q1 2026.
• A 5-year average of $696.6 million and a median of $735.2 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2026: Common Equity rose 8.56% in 2022, then tumbled 52.14% in 2026.
• A 5-year view of Common Equity shows it stood at $885.8 million in 2022, then retreated by 11.58% to $783.2 million in 2023, then dropped by 10.48% to $701.1 million in 2024, then plunged by 47.51% to $368.0 million in 2025, then slipped by 8.32% to $337.4 million in 2026.
• Business Quant data shows MYGN's Common Equity at $337.4 million in Q1 2026, $368.0 million in Q4 2025, and $372.8 million in Q3 2025.